Avonex®
Quick Facts
Avonex® is an interferon beta-1a immune system modulator with antiviral properties.
Self-injected into muscle
Weekly
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
Over two years, Avonex®:
- Reduced relapses by 32% compared with placebo.
- 78% of people taking Avonex had no increase in disability, compared with 65% of people taking placebo.
- On MRI, Avonex reduced the number of gadolinium-enhanced (Gd+) lesions by 75%.
Common Potential Side Effects
Flu-like symptoms, upper respiratory infection, white blood cell count and liver test abnormalities.
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Biogen
HOW Avonex® WORKS
Avonex® is a self-administered weekly injection of a group of proteins called interferon beta-1a. Interferon beta-1a is also naturally produced by the body to help fight viruses. This disease-modifying therapy is thought to help decrease inflammation that can cause MS flare-ups by helping to control immune system activities.
FDA-Approved
Avonex® was FDA-approved in 1996 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.
Potential Side Effects
Flu-like symptoms and headache, upper respiratory infection (e.g., common cold), sinusitis, Urinary Tract Infection (UTI), white blood count and liver test abnormalities. Side effects are usually temporary and manageable. Rare adverse events include depression, problems with white blood cell count, thyroid problems, seizures and liver damage.
OTHER KEY INFORMATION
Testing completed prior to starting Avonex®:
- Complete blood and differential white blood cell counts
- Blood chemistry panel including liver function tests
- Thyroid function tests
Testing after starting Avonex®:
- Liver enzymes
- Test number of red blood cells and white blood cells.
- Monitor possible development of neutralizing antibodies.